Physicians' Academy for Cardiovascular Education

Innovation

News, updates and resources on novel developments on the forefront of clinical science in cardiovascular medicine.

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

3' education - Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##SCROLLER_ITEMS_FULL_TITLE##

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

Pharmacodynamics of investigational pre-beta HDL-mimicking agent

3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
##SCROLLER_ITEMS_FULL_TITLE##

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
##SCROLLER_ITEMS_FULL_TITLE##

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##SCROLLER_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##SCROLLER_ITEMS_FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays

Irregular sleep duration and timing associated with increased risk of CVD

Literature - Mar. 24, 2020 - Huang T et al., - J Am Coll Cardiol. 2020.

Using data from the MESA study, it was demonstrated that individuals with irregular sleep duration and timing have increased risk of CVD.

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018
Learn more about the mission of PACE-CME

Learn more about PACE-CME, our mission, our programmes and our cardiovascular educational services and resources

Inflammatory response is activated in end stage HF: a potential new therapeutic target?

News - Apr. 24, 2018

A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.

First-in-class cholesterol synthesis inhibitor meets primary endpoint in phase 3 study

News - Mar. 7, 2018

Phase 3 study data with bempedoic acid show 28% additional LDL-c lowering on background therapy and 33% reduction of hsCRP in patients with atherosclerotic CVD or at high risk for ASCVD.

Development of a cheaper, small biologic alternative to PCSK9 antibodies to lower LDL-c

News - Mar. 6, 2018

A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.

New antidiabetic agent favorably affects glucose regulation and lipid profile

News - Mar. 6, 2018

12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.

Preclinical and clinical studies strengthen the promise of ANGPTL3 as a therapeutic target

Literature - May 30, 2017

Genetic and therapeutic antagonism of angiopoietin-3 in humans and mice improved lipid profiles and lowered CV risk, and oligonucleotide-based inhibition of Angptl3 in mice slowed atheroprogression.

Monoclonal antibody to ANGPTL3 receives FDA Breakthrough Therapy designation for HoFH

News - Apr. 11, 2017

Evinacumab is directed against angiopoietin-like protein 3, which acts as an inhibitor of lipoprotein lipase and endothelial lipase. Positive interim phase 2 results with evinacumab have been reported in HoFH.

Long-term sustained BP reductions with baroreflex activation therapy

Literature - Mar. 27, 2017 - de Leeuw PW et al. - Hypertension 2017;69: published online ahead of print

Baroreflex activation therapy lowers BP in the long-term, in treatment-resistant hypertensive patients, particularly in those with HF and preserved ejection fraction.

No effect of PCSK9 inhibitor on cognitive functioning in CVD patients, even at LDL-c <25 mg/dL

Presented at ACC.17 by Robert P. Giugliano

News - Mar. 18, 2017

ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.

Sustained LDL-c lowering up to 360 days with siRNA directed against PCSK9 in phase 2 study

Presented at ACC.17 by Kausik Ray

News - Mar. 16, 2017

ACC 2017 Inclisiran, which prevents PCSK9 protein production, resulted in long-term LDL-c lowering after two doses of siRNA, without safety concerns, in the ORION-1 study.

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.